On June 18th the winner of this year’s Global Entrepreneurship Competition, held in Barcelona, will be announced, and Cambridge-based Horizon Discovery has been selected as a finalist.
Horizon Discovery ia a finalist in Global Entrepreneurship Competition
HIT-Barcelona’09 is an international summit bringing together CEOs, directors of innovation, entrepreneurs and investors from around the world in Barcelona from June 17 to 19, 2009. Entries for the competition have been selected from among the best entrepreneurial projects by representatives from top entrepreneurship centres (business schools, incubators, technology parks, universities, angel investor networks, etc.) from around the world. Horizon is one of only two short-listed UK companies.
Horizon Discovery, which began commercial operation in July 2007, is fast becoming a world leader in the supply of tools and services to the pharmaceutical industry that enable the discovery of new cancer therapies targeted at genetically-defined patient populations. The company is part of University of Cambridge’s commercialisation office, Cambridge Enterprise Limited, portfolio of investment companies.
Horizon’s award winning (UK Medical Futures Innovation in Cancer 2008) GENESISTM technology is a gene engineering platform that uses a proprietary viral DNA construct with a vastly improved ability to target any pre-determined endogenous gene location in human cells grown in culture. The result is a means of generating accurate and stable functional models of complex disease states that can be readily deployed in existing drug discovery and development programmes.
The company has developed a portfolio of 150+ products and is building license, service and collaborative relationships with the world’s leading pharmaceutical companies including Genentech, Novartis, Millennium and OSI Pharmaceuticals who recognise that the traditional approach of ‘one-size-fits-all’ approach in search of new cancer drugs is no longer sufficient. Horizon’s tools and services provide a better way for researchers to develop drugs which will provide individual patient care.
About Horizon Discovery
Horizon Discovery is a translational genomics company founded in June 2007 and is headquartered at the Babraham Research Campus, Cambridge, UK and with additional research laboratories in Torino, Italy. Horizon’s goal is to convert new information on the genetic causes of cancer into laboratory models that will facilitate the discovery of drugs that target these defects. Central to this aim is Horizon Discovery’s offering of isogenic cell-lines, which represent accurate models of defined cancer patient populations and their matched normal genetic backgrounds – a missing link in the rational and efficient development of novel targeted anti-cancer agents.
Contact: Dr Darrin M Disley on +44 (0)1223 303049 or +44 (0)7786 133893
Cambridge Enterprise Seed Funds is part of Cambridge Enterprise Limited and provides funding for early stage businesses that have been founded by members of the University of Cambridge. Cambridge Enterprise Seed Funds comprises the University Challenge Fund, the University Venture Fund and the University of Cambridge Discovery Fund. The University Challenge Fund was established in 2000 as a result of a government initiative, with start up money from the University of Cambridge, the Wellcome Trust, the Gatsby Foundation and the Office of Science & Technology. The University Venture Fund was set up in 1995 with Funds solely from the University of Cambridge. The University of Cambridge Discovery Fund was launched in September 2008. All three funds are evergreen and use equity realisations to continue funding new businesses.
Cambridge Enterprise Limited is a wholly owned subsidiary of the University of Cambridge, responsible for the commercialisation of University intellectual property. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring, specialist Surgeries and other related programmes. In 2007/08 income from licensing, consultancy and equity transactions exceeded £10 million, of which £8 million represents distributions to University departments and academics
For further information please contact:
Head of Marketing
Cambridge Enterprise Limited
Tel: 01223 760 339
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.